Abstract
Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 224-232 |
| Number of pages | 9 |
| Journal | Cardiology |
| Volume | 129 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 16 2014 |
Fingerprint
Keywords
- Acute coronary syndrome
- Coagulation pathway
- Factor Xa
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
- Pharmacology (medical)
- Medicine(all)
Cite this
Role of oral factor Xa inhibitors after acute coronary syndrome. / Sharma, Abhishek; Garg, Akash; Borer, Jeffrey S.; Krishnamoorthy, Parasuram; Garg, Jalaj; Lavie, Carl J.; Zadeh, Armin; Mukherjee, Debabrata; Ahmad, Hasan; Lichstein, Edgar.
In: Cardiology, Vol. 129, No. 4, 16.04.2014, p. 224-232.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Role of oral factor Xa inhibitors after acute coronary syndrome
AU - Sharma, Abhishek
AU - Garg, Akash
AU - Borer, Jeffrey S.
AU - Krishnamoorthy, Parasuram
AU - Garg, Jalaj
AU - Lavie, Carl J.
AU - Zadeh, Armin
AU - Mukherjee, Debabrata
AU - Ahmad, Hasan
AU - Lichstein, Edgar
PY - 2014/4/16
Y1 - 2014/4/16
N2 - Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.
AB - Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic events, but the overall benefits were offset by increased bleeding complications. Recently, there has been increased interest in the potential role of new oral anticoagulants, some of which target factor Xa, after ACS. Factor Xa is important for the coagulation pathway and also plays a role in cellular proliferation and inflammation. It may thus be an attractive target for therapeutic intervention in ACS. Recently, various oral factor Xa inhibitors have been studied as potential treatment options for ACS. This review will focus on currently available data to evaluate the possible role of factor Xa inhibitors in the management of patients with ACS.
KW - Acute coronary syndrome
KW - Coagulation pathway
KW - Factor Xa
UR - http://www.scopus.com/inward/record.url?scp=84911481047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84911481047&partnerID=8YFLogxK
U2 - 10.1159/000368747
DO - 10.1159/000368747
M3 - Article
C2 - 25402219
AN - SCOPUS:84911481047
VL - 129
SP - 224
EP - 232
JO - Journal of Cardiovascular Medicine
JF - Journal of Cardiovascular Medicine
SN - 1558-2027
IS - 4
ER -